Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (NURPF)
OTHER OTC:NURPF
RESEARCH TOOLSreports
Total Valuation
Neuren Pharmaceuticals Limited has a market cap or net worth of $769.97M. The enterprise value is $2.57B.
Market Cap$769.97M
Enterprise Value$2.57B
Share Statistics
Neuren Pharmaceuticals Limited has 127.99M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding127.99M
Owened by Insiders0.02%
Owened by Instutions<0.01%
Financial Efficiency
Neuren Pharmaceuticals Limited’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$24,165,750
Profits Per Employee$14,661,500
Employee Count8
Asset Turnover0.94
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuren Pharmaceuticals Limited is 20.08. Neuren Pharmaceuticals Limited’s PEG ratio is <0.01.
PE Ratio20.08
PS Ratio13.60
PB Ratio15.37
Price to Fair Value15.37
Price to FCF17.06
Price to Operating Cash Flow17.05
PEG Ratio<0.01
Income Statement
In the last 12 months, Neuren Pharmaceuticals Limited had revenue of $193.33M and earned $117.29M in profits. Earnings per share was $0.92.
Revenue$193.33M
Gross Profit$159.78M
Operating Income$137.26M
Pretax Income$167.34M
Net Income$117.29M
EBITDA155.17M
Earnings Per Share (EPS)0.92
Cash Flow
In the last 12 months, operating cash flow was $119.51M and capital expenditures -$25.00K, giving a free cash flow of $119.49M billion.
Operating Cash Flow$119.51M
Free Cash Flow$119.49M
Free Cash Flow per Share$0.93
Dividends & Yields
Neuren Pharmaceuticals Limited pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.85
52-Week Price Change-44.29%
50-Day Moving Average7.79
200-Day Moving Average9.31
Relative Strength Index (RSI)32.63
Average Volume (3m)212.00
Important Dates
Neuren Pharmaceuticals Limited upcoming earnings date is Aug 26, 2025, TBA.
Last Earnings DateFeb 27, 2025
Next Earnings DateAug 26, 2025
Ex-Dividend Date―
Financial Position
Neuren Pharmaceuticals Limited as a current ratio of 5.78, with Debt / Equity ratio of 0.00
Current Ratio5.78
Quick Ratio5.78
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuren Pharmaceuticals Limited has paid $50.05M in taxes.
Income Tax$50.05M
Effective Tax Rate23.43%
Enterprise Valuation
Neuren Pharmaceuticals Limited EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Neuren Pharmaceuticals Limited has $213.17M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$213.17M billion.
Cash & Marketable Securities$213.17M
Total Debt$0.00
Net Cash-$213.17M
Net Cash Per Share-$1.67
Tangible Book Value Per Share$1.61
Margins
Gross margin is 88.47%, with operating margin of 74.37%, and net profit margin of 67.73%.
Gross Margin88.47%
Operating Margin74.37%
Pretax Margin88.45%
Net Profit Margin67.73%
EBITDA Margin85.92%
EBIT Margin85.89%
Analyst Forecast
The average price target for Neuren Pharmaceuticals Limited is $16.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.70
Price Target Upside139.26%
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast
EPS Growth Forecast